Zuo Dian-Bao, Wang Chun-Hua, Sang Ming, Sun Xiao-Dong, Chen Guo-Ping, Ji Kang-Kang
Research Center for Translational Medicine, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang 441000, Hubei Province, China.
Central Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China.
World J Diabetes. 2025 Jul 15;16(7):107344. doi: 10.4239/wjd.v16.i7.107344.
Diabetes mellitus, a global epidemic, represents a major public health threat. Stem cell therapy, with its regenerative capacity, has emerged as a promising approach for diabetes mellitus management. This paper reviews recent advancements, prospects, and challenges in stem cell-based treatments for diabetes mellitus, focusing on the applications of induced pluripotent stem cells and mesenchymal stem cells, the development of pancreatic islet organoids, and the potential for personalized medicine. The review critically assesses the efficacy and safety of stem cell therapies in clinical trials and examines their applications in both type 1 and type 2 diabetes mellitus. Despite the promising potential, challenges such as safety concerns, transplantation efficiency, ethical considerations, and immune rejection remain prevalent. Lastly, the paper discusses future directions, including the integration of stem cell therapy with other treatments and the advancement of personalized therapeutic strategies, offering new perspectives and hope for diabetes mellitus management.
糖尿病是一种全球性的流行病，是对公众健康的重大威胁。具有再生能力的干细胞疗法已成为治疗糖尿病的一种有前景的方法。本文综述了基于干细胞治疗糖尿病的最新进展、前景和挑战，重点关注诱导多能干细胞和间充质干细胞的应用、胰岛类器官的发展以及个性化医疗的潜力。该综述批判性地评估了干细胞疗法在临床试验中的疗效和安全性，并研究了它们在1型和2型糖尿病中的应用。尽管潜力巨大，但安全问题、移植效率、伦理考量和免疫排斥等挑战仍然普遍存在。最后，本文讨论了未来的方向，包括将干细胞疗法与其他治疗方法相结合以及推进个性化治疗策略，为糖尿病管理提供了新的视角和希望。
